COI Statements for Drug and Alcohol Dependence Editors

July, 2017

Jan Copeland is an Honorary Professor in the Faculty of Medicine at the University of New South Wales. She is Director of her own consultancy service, Cannabis Information and Support. She was founding and sole Director (2008-2016) of the National Cannabis Prevention and Information Centre (NCPIC) prior to its defunding by Australia’s Turnbull Coalition Government. She is a past recipient of a NIDA research grant, grants from the Australian National Health and Medical Research Council, the NSW Health Department, ZonMW and the Australian Rotary Health Fund. Each year she typically receives honoraria to attend conferences or provide training. Elsevier, the owner and publisher of Drug and Alcohol Dependence, provides an honorarium to Dr. Copeland for her efforts as an Associate Editor of the journal. Dr. Copeland has never received any funds from pharmaceutical companies but is involved in a clinical trial of a medication that is being provided free of charge by the manufacturer. Dr. Copeland has no investments in pharmaceutical, tobacco, or alcohol beverage or other firms with entrepreneurial activities pertinent to her service as Associate Editor aside from possible inclusion in superannuation funds over which she has no control as an individual investor. (Updated July, 2017)

Eske Derks is group leader in Translational Neurogenomics at QIMR Berghofer. Her academic salary is provided by QIMR Berghofer, a not-for-profit medical research institute. Dr. Derks is a current and past recipient of research grants from the Netherlands Organisation for Scientific Research (NWO), the Foundation Volksbond Rotterdam, and the University of Amsterdam. Elsevier, the owner and publisher of Drug and Alcohol Dependence, provides an honorarium to Dr. Derks for her efforts as an Associate Editor of the journal. Dr. Derks has received honoraria for invited lectures from Illumina, and from various academic institutions. Dr. Derks currently has no other investments in pharmaceutical, tobacco, or alcohol beverage or other firms with entrepreneurial activities pertinent to her service as Associate Editor aside from possible inclusion in mutual funds over which she has no control as an individual investor. (Updated July, 2017)

Kyle M. Kampman is a Professor in the Department of Psychiatry at The University of Pennsylvania School of Medicine. His academic salary is supported by grants from the NIH as well as funds from the University of Pennsylvania. In the past three years, he has received honoraria for his services on behalf of the U.S. federal government (e.g., grant reviews) and from academic medical centers (e.g., providing grand rounds). He also has received grant funding from Indivior, Alkermes, and Opiant. He is a consultant for Opiant. Elsevier, the owner and publisher of Drug and Alcohol Dependence, provides an honorarium to Dr. Kampman for his efforts as an Associate Editor of the journal. Dr. Kampman currently has no investments in pharmaceutical, tobacco, or alcohol beverage or other firms with entrepreneurial activities pertinent to his service as an Associate Editor, aside from possible
inclusion in mutual funds over which he has no control as an individual investor.  (Updated July, 2017)

**Katherine M. Keyes** is an Associate Professor of Epidemiology in the Department of Epidemiology in the Mailman School of Public Health, Columbia University. Her academic salary is provided by a K01 grant from NIAAA, and from the Department of Epidemiology. She is also the recipient of grants from NIAAA and NIDA for which she does not draw salary but conducts research. Each year she typically receives modest honoraria from academic medical centers (e.g., providing grand rounds). Elsevier, the owner and publisher of Drug and Alcohol Dependence, provides an honorarium to Dr. Keyes for her efforts as an Associate Editor of the journal. Dr. Keyes currently has no investments in pharmaceutical, tobacco, or alcohol beverage or other firms with entrepreneurial activities pertinent to her service as an Associate Editor aside from possible inclusion in mutual funds over which she has no control as an individual investor.  (Updated July, 2017)

**Adam M. Leventhal** is an Associate Professor in the Departments of Preventive Medicine and Psychology and USC Norris Comprehensive Cancer Center at the University of Southern California. His academic salary is provided by funds from the University of Southern California and grants from the NIH and American Cancer Society. Each year he typically receives honoraria for his services on behalf of the U.S. federal government (e.g., grant reviews) and from academic medical centers (e.g., speaking engagements, research consulting). Elsevier, the owner and publisher of Drug and Alcohol Dependence, provides an honorarium to Dr. Leventhal for his efforts as an Associate Editor of the journal. Dr. Leventhal currently has no investments in pharmaceutical, tobacco, or alcohol beverage or other firms with entrepreneurial activities pertinent to his service as an Associate Editor aside from possible inclusion in mutual funds over which he has no control as an individual investor. (Updated July, 2017)

**Lin Lu** is a Professor and the Director of National Institute of Mental Health and National Insitute on Drug Dependence, Peking University, China. He has a full-time appointment at Peking University Health Science Center and his academic salary is provided directly by Peking University. Dr. Lu is a current and past recipient of research grants from Natural Science Foundation of China and Department of Nature and Science, China. Each year he typically receives honoraria for his services on behalf of the China government (e.g., committee meetings). He also receives small royalties from textbooks he has co-edited. Elsevier, the owner and publisher of Drug and Alcohol Dependence, provides an honorarium to Dr. Lu for his efforts as an Associate Editor of the journal. In the past three years Dr. Lu has received a modest outside income by providing consulting and speaking services to pharmaceutical companies and other related health service companies. Dr. Lu currently has no other investments in pharmaceutical, tobacco, or alcohol beverage or other firms with entrepreneurial activities pertinent to his service as Associate Editor aside from possible inclusion in mutual funds over which he has no control as an individual investor.  (Updated July, 2017)
Linda J. Porrino is a Professor and Chair of the Department of Physiology and Pharmacology at Wake Forest School of Medicine. Her academic salary is provided by grants from the National Institute of Health, as well as funds from Wake Forest School of Medicine. Dr. Porrino is a current and past recipient of NIDA and NIAAA research grants, as well as grants from the Defense Advanced Research Programs Agency. Each year she typically receives honoraria for her services on behalf of the U.S. federal government (e.g., grant reviews) and from academic medical centers (e.g., providing grand rounds). Elsevier, the owner and publisher of Drug and Alcohol Dependence, provides an honorarium to Dr. Porrino for her efforts as an Associate Editor of the journal. Dr. Porrino currently has no investments in pharmaceutical, tobacco, or alcohol beverage or other firms with entrepreneurial activities pertinent to her service as an Associate Editor aside from possible inclusion in mutual funds over which she has no control as an individual investor. (Updated July, 2017)

Craig R. Rush is a Professor in the Departments of Behavioral Science, Psychiatry and Psychology at the University of Kentucky, as well as Vice Chair for Research in the Department of Psychiatry. His academic salary is provided by funds from the University of Kentucky. Dr. Rush is a current and past recipient of NIDA research grants. Each year he typically receives honoraria for his services on behalf of the U.S. federal government (e.g., grant reviews) and from academic medical centers (e.g., speaking engagements). Elsevier, the owner and publisher of Drug and Alcohol Dependence, provides an honorarium to Dr. Rush for his efforts as an Associate Editor of the journal. In the past three years, Dr. Rush has served as an expert reviewer of forensic cases (with reimbursement for these services by local law firms associated with these cases). Dr. Rush currently has no investments in pharmaceutical, tobacco, or alcohol beverage or other firms with entrepreneurial activities pertinent to his service as an Associate Editor aside from possible inclusion in mutual funds over which he has no control as an individual investor. (Updated July, 2017)

Steven Shoptaw is Professor and Vice Chair for Research in the Department of Family Medicine and Professor in the Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine at the University of California, Los Angeles. He is also Professor (Hon) in the Department of Psychiatry at the University of Cape Town. He is Executive Director of the UCLA Center for Behavioral & Addiction Medicine (CBAM) and is Director of the NIMH-funded, UCLA Center for HIV Identification Prevention and Treatment Services (CHIPTS). His salary support is provided in part from the University of California and research grants from the National Institute of Health. Dr. Shoptaw receives small honoraria each year for professional services he provides in conducting grant reviews, in consulting for think tanks, and in presenting at medical and scientific conferences. Currently or in the past, Dr. Shoptaw has no investments in pharmaceutical, tobacco, alcohol beverage or other firms with entrepreneurial activities. Dr. Shoptaw has received clinical supplies for his research work from Gilead Sciences, Inc., Cephalon, Inc.,
Medicinova, Inc., and Pfizer, Inc. He receives an honorarium from Elsevier for his service as an Associate Editor of Drug and Alcohol Dependence. (Updated July, 2017)

Eric C. Strain is a Professor in the Department of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine. His academic salary is provided by grants from the National Institute on Health, as well as funds from Johns Hopkins University. Dr. Strain is a current and past recipient of NIDA research grants and NIAAA contracts. Each year he typically receives small honoraria for his services on behalf of the U.S. federal government (e.g., grant reviews) and from academic medical centers (e.g., providing grand rounds). He also receives modest royalties from textbooks he has co-edited. Elsevier, the owner and publisher of Drug and Alcohol Dependence, provides an honorarium to Dr. Strain for his efforts as Editor-in-Chief of the journal. The publisher also provides some funds to cover editorial expenses in the journal office. In the past three years Dr. Strain has received outside income by providing consulting and advisory board services to pharmaceutical companies, a health service company, and expert work on forensic cases. In the past three years he has provided consulting and advisory board services to pharmaceutical companies (Egalet Pharmaceuticals, Indivior Pharmaceuticals, Relmada Pharmaceuticals), he has received research contracts from companies for drug-related research (Alkermes, Fast-Track Drugs and Biologics), consulted for health service companies (The Oak Group, Pinney Associates), and served as an expert review for forensic cases (with reimbursement for these services by local and national law firms associated with these cases). Dr. Strain’s family has small equity holdings in companies with prominent sales of caffeine-containing beverages, and in one pharmaceutical company (Gilead Sciences). Dr. Strain currently has no other investments in pharmaceutical, tobacco, or alcohol beverage or other firms with entrepreneurial activities pertinent to his service as Editor-in-Chief aside from possible inclusion in mutual funds over which he has no control as an individual investor. (Updated July, 2017)